Source: Pharmaceutical Business Review

Homology: Q32 Bio to merge with Homology Medicines

Homology Medicines will issue shares of its common stock to Q32 Bio stockholders as part of the merger deal, in return for cancelling Q32 Bio's capital stock. Pre-merger The post Q32 Bio to merge with Homology Medicines appeared first on Pharmaceutical Business review.

Read full article »
Homology's Competitors | Homology's News | Homology's Financials
Stay up-to-date with the latest news on Homology
Annual Revenue
$100K-5.0M
Employees
1-25
Albert Seymour's photo - President & CEO of Homology

President & CEO

Albert Seymour

CEO Approval Rating

82/100

Read more
Stay up-to-date with the latest news on Homology